Compare WINA & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | REPL |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2006 | 2018 |
| Metric | WINA | REPL |
|---|---|---|
| Price | $272.30 | $20.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $23.33 |
| AVG Volume (30 Days) | 70.5K | ★ 3.2M |
| Earning Date | 10-14-2026 | 10-28-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 3.76 | N/A |
| EPS | ★ 8.51 | N/A |
| Revenue | ★ $86,055,700.00 | N/A |
| Revenue This Year | $12.61 | N/A |
| Revenue Next Year | $44.75 | $513.15 |
| P/E Ratio | $32.27 | ★ N/A |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $261.71 | $1.50 |
| 52 Week High | $488.83 | $23.64 |
| Indicator | WINA | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 65.49 |
| Support Level | $261.71 | $7.11 |
| Resistance Level | $293.75 | N/A |
| Average True Range (ATR) | 10.08 | 1.65 |
| MACD | 0.02 | 0.50 |
| Stochastic Oscillator | 34.22 | 75.81 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment, including Franchising, and one non-reportable segment, Leasing. The franchising segment franchises value-oriented retail stores that buy, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes the middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.